Filter posts

Oncolytics® Biotech Inc. issues 33rd U.S. patent

Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) has been granted its 33rd U.S. Patent, No. …

Biotech and the flu pandemic

Biotechnology researchers are working to create new vaccination options to help stop the next big …

Panelists ponder when the window will open

Panelists in this afternoon’s business roundtable “Window Shopping – The Buyer’s Perspective on Today’s IPO …

Healthcare reform: sustaining biotech innovation in a new world

The Eighth Annual BIO Investor Forum kicked off today with a plenary session on health …

Guest blogger post: The Lure of Translational Research

As a breast cancer advocate, I am seduced by the lure of translational research and …

The Burrill Report Interview with Jim Greenwood

The Burrill Report’s Daniel Levine spoke with Jim Greenwood, president and CEO of BIO, about …

Development continues for osteoporosis drug

Osteologix, Inc. (OLGX.OB) will continue the clinical development for its osteoporosis drug, NB S101 (strontium …

Oncolytics invests in private biotech company

Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) invested in British Canadian Biosciences Corp., a privately …

Podcast with Fast Forward's Tim Coetzee

Biotech Now’s Tracy Krughoff spoke with Dr. Tim Coetzee, president of Fast Forward, a subsidiary …

Q&A with Complete Genomics' Dr. Clifford Reid

Read a recent interview with Complete Genomics Chairman, President, and CEO Clifford Reid about his …